𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus

✍ Scribed by Lazar Vujanovic; Theresa L. Whiteside; Douglas M. Potter; Jessica Chu; Soldano Ferrone; Lisa H. Butterfield

Book ID
105967454
Publisher
Springer-Verlag
Year
2008
Tongue
English
Weight
735 KB
Volume
58
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficiency of cross presentation of vacc
Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells
✍ Marie Larsson; Jean-Francois Fonteneau; Selin Somersan; Catherine Sanders; Kara 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB 👁 2 views

Dendritic cells (DC) utilize at least two pathways to process viral antigens onto MHC class I molecules. The conventional endogenous route is used to acquire antigens from both infectious and non-replicating virions. Exogenous pathways are used by DC to acquire and "cross-present" antigens derived f

Contrasting cytoskeletal regulation of M
Contrasting cytoskeletal regulation of MHC class II peptide presentation by human B cells or dendritic cells
✍ Alix Delaguillaumie; Viviana Marin-Esteban; Niclas Setterblad; Laurence Jeanson 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB

## Abstract MHC class II‐mediated antigen presentation by B lymphocytes or dendritic cells (DC) initiates CD4^+^ T lymphocyte activation. In B lymphocytes, MHC class II peptide presentation has been characterised by recruitment of MHC class II, F‐actin and lipid rafts to the B cell–T cell immunolog

Recombinant E. coli efficiently delivers
Recombinant E. coli efficiently delivers antigen and maturation signals to human dendritic cells: Presentation of MART1 to CD8+ T cells
✍ Kristen J. Radford; Andrew M. Jackson; Jui-Ho Wang; Georges Vassaux; Nicholas R. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 432 KB

## Abstract The generation of tumour‐specific cytotoxic T‐lymphocyte (CTL) responses is the primary focus in the design of immunotherapeutic cancer vaccines. We have recently demonstrated generation of ovalbumin (OVA)‐specific CTLs and tumour‐protection in a murine tumour model using vaccination wi